FOLH1 and neoplasm: Four patients experienced molecular CR, with disappearance of all PSMA-avid tumor lesions (exceeding the SUV threshold of 4.0), 24 (60.0%) patients had PR, 4 (10.0%) SD, and 8 (20.0%) PD, with various numbers of new PSMA-positive foci (Table 3).